Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

Overview

RATIONALE: Surgery to remove axillary lymph nodes may be an effective treatment for women with breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of therapy with or without axillary lymph node dissection following quadrantectomy in treating older women with stage I breast cancer that is estrogen receptor positive.

Full Title of Study: “QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Primary Purpose: Treatment

Detailed Description

OBJECTIVES: – Compare the efficacy of quadrantectomy with or without axillary lymph node dissection, followed by tamoxifen in terms of local and distant relapse rates and overall survival of patients with stage I, invasive breast cancer. – Determine the relationship between biological variables, such as hormone receptor status, cell proliferation, and DNA ploidy, and the clinical outcome of the disease in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified by center. Patients are randomized to 1 of 2 treatment arms. – Arm I: Patients undergo quadrantectomy with dissection of level I and II axillary lymph nodes. – Arm II: Patients undergo quadrantectomy without axillary lymph node dissection. Patients on both arms receive tamoxifen daily for 5 years. Patients are followed every 4 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 642 patients will be accrued for this study within 3 years.

Interventions

  • Drug: tamoxifen citrate
  • Procedure: conventional surgery

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Histologically proven stage I, invasive breast cancer – Hormone receptor status: – Estrogen receptor positive – Progesterone receptor positive or negative PATIENT CHARACTERISTICS: Age: – 65 to 80 Sex: – Female Menopausal status: – Postmenopausal Performance status: – Not specified Life Expectancy: – Not specified Hematopoietic: – Not specified Hepatic: – Not specified Renal: – Not specified Other: – No serious disease that would preclude surgery – No other prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: – Not specified

Gender Eligibility: Female

Minimum Age: 65 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Institute of Oncology
  • Overall Official(s)
    • Gabriele Martelli, MD, Study Chair, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.